# Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

> **NCT01188564** · PHASE3 · COMPLETED · sponsor: **Pharming Technologies B.V.** · enrollment: 75 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** rhC1INH
- **DRUG:** Placebo (Saline)

## Key facts

- **NCT ID:** NCT01188564
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-03
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2015-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188564, "Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01188564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*